Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (1): 65-69    DOI: 10.31083/j.ejgo.2020.01.4887
Original Research Previous articles | Next articles
Expression and therapeutic potential of macrophage migration inhibitory factor and CD74 in ovarian cancer
Y. S. Lee1, J. M. Baek1, E. K. Park2, C. J. Kim1, H. J. Lee3, J. O. Kim4, *()
1 Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul, Republic of Korea
2 Department of General Surgery, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul, Republic of Korea
3 Department of Pathology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Wonmi-gu, Bucheon, Gyeonggi-do, Republic of Korea
4 Department of Pathology, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Jung-gu, Daejeon, Republic of Korea
Download:  PDF(535KB)  ( 298 ) Full text   ( 4 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose of Investigation: To evaluate macrophage migration inhibitory factor (MIF) and CD74 expression in ovarian cancer, and to explore whether these expression levels correlate with clinicopathologic parameters. Materials and Methods: A total of 151 tissue samples were collected from May 2009 through May 2015. The collected samples included ten normal ovaries, 41 benign epithelial ovarian tumors, 38 borderline tumors, and 62 malignant epithelial ovarian tumors. CD74 and MIF expression was assessed by immunohistochemistry and a retrospective study was conducted. Results: Immunohistochemical analysis showed that MIF and CD74 expression was significantly higher in ovarian tumors, including ovarian cancer, than in normal ovary tissues. Furthermore, high MIF expression was correlated with lymph node metastasis (p = 0.048) and ovary surface invasion (p = 0.039). Conclusion: The present findings suggest that co-expression of MIF and CD74 in ovarian cancer is associated with poor clinical parameters and may serve as a therapeutic target for the treatment of ovarian cancer.
Key words:  Ovarian tumor      CD74      Macrophage migration inhibitory factor (MIF)      Immunohistochemistry     
Published:  15 February 2020     
Fund: 
Catholic Medical Center Research Foundation
*Corresponding Author(s):  JONG OK KIM     E-mail:  jkim@catholic.ac.kr

Cite this article: 

Y. S. Lee, J. M. Baek, E. K. Park, C. J. Kim, H. J. Lee, J. O. Kim. Expression and therapeutic potential of macrophage migration inhibitory factor and CD74 in ovarian cancer. European Journal of Gynaecological Oncology, 2020, 41(1): 65-69.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.01.4887     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I1/65

[1] Jaudah Al-Maghrabi, Haneen Al-Maghrabi. SIRT1 is overexpressed in endometrial adenocarcinoma: a tissue microarray analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 699-704.
[2] Jisu Yeom, Seulki Lee, Youngsun Kim. Hypercalcemia associated with primary mucinous ovarian tumor followed by pseudomyxoma peritonei can be fatal: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 824-827.
[3] Wook Youn Kim, Shin Hee Seo, Seung-Hyuk Shim, Jin Hee Park, Hyung Kyu Park, Kyeong A So, Tae Jin Kim, Sun Joo Lee. Correlation of immunohistochemistry and silver in situ hybridization for the assessment of c-MET in uterine cervical cancer patients treated with radical hysterectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 745-752.
[4] Adrius Gaurilcikas, Migle Gedgaudaite, Saulius Paskauskas, Tomas Birzietis, Daiva Vaitkiene. Unusual case of Krukenberg tumors diagnosed in early pregnancy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 806-809.
[5] Hyang Sook Jeong, Yuki Gen, Hui Ryun Joo, Ji Geun Yoo, Seung Geun Yeo, Dong Choon Park. Mesonephric-like carcinoma of the uterine corpus: A case report and literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 664-667.
[6] Soo-Young Lee, Dae-Hyung Lee. Perivascular epithelioid cell tumor arising in the left parametrium: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 657-660.
[7] S.R Oh, J.-W. Park. Is the Risk of Malignancy Index a predictive tool for preoperative differentiation between borderline ovarian tumor and ovarian cancer?[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 368-374.
[8] Sung-Im Do, Hee-Chul Shin, Hee Sung Kim. Clinical significance of MET receptor protein and mRNA expression in invasive breast cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 240-245.
[9] T. Armeanu, R. Maftei, G. Simionescu, D. Nicolaiciuc, N. Plopa, B. Doroftei. Infertility and borderline malignant ovarian tumors: a case of successful pregnancy after fertility-preserving management of the disease[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 284-288.
[10] Z. Xu, H. Wen, Q. Xue. Successful pregnancy achieved by in vitro fertilization after fertility-preserving treatments in an infertile woman with borderline ovarian tumor and endometrial complex atypical hyperplasia: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 126-129.
[11] M.H. Hajeer, A. Al Khader, N.A. Shahin, M.S. Bata. Negative p53 expression and negative high risk HPV in a 26-year-old lady with vulvar keratinizing squamous cell carcinoma: report of a case[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 130-133.
[12] N. K. Šuster, M. Meznaric, N. Škorja, I. Virant-Klun, I. Verdenik, Š. Smrkolj. Cancer stem cell-related marker NANOG expression in ovarian serous tumors using Western blotting and immunohistochemistry: comparison of two techniques[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 948-952.
[13] L. N. Abaid, N. Zekry, A. Ronaghi, R. C. Kankus, B. H. Goldstein. Primary management of an extremely large, invasive mucinous ovarian adenocarcinoma: a case report[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1044-1046.
[14] Yangyang Shi, Yongyun Shi, Dabao Wu. A case of placental site trophoblastic tumor and a retrospective analysis[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1096-1099.
[15] H. Ibrahim, K. Dresser, K. M. Cornejo. Loss of 5-hydroxymethylcytosine (5-hmC) expression in endometrioid type endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 846-848.
No Suggested Reading articles found!